The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Differential Immune Responses and Protective Efficacy Induced by Components of a Tuberculosis Polyprotein Vaccine, Mtb72F, Delivered as Naked DNA or Recombinant Protein
Open accessAbstract
Key Ags of Mycobacterium tuberculosis initially identified in the context of host responses in healthy purified protein derivative-positive donors and infected C57BL/6 mice were prioritized for the development of a subunit vaccine against tuberculosis. Our lead construct, Mtb72F, codes for a 72-kDa polyprotein genetically linked in tandem in the linear order Mtb32C-Mtb39-Mtb32N. Immunization of C57BL/6 mice with Mtb72F DNA resulted in the generation of IFN-γ responses directed against the first two components of the polyprotein and a strong CD8+ T cell response directed exclusively against Mtb32C. In contrast, immunization of mice with Mtb72F protein formulated in the adjuvant AS02A resulted in the elicitation of a moderate IFN-γ response and a weak CD8+ T cell response to Mtb32c. However, immunization with a formulation of Mtb72F protein in AS01B adjuvant generated a comprehensive and robust immune response, resulting in the elicitation of strong IFN-γ and Ab responses encompassing all three components of the polyprotein vaccine and a strong CD8+ response directed against the same Mtb32C epitope identified by DNA immunization. All three forms of Mtb72F immunization resulted in the protection of C57BL/6 mice against aerosol challenge with a virulent strain of M. tuberculosis. Most importantly, immunization of guinea pigs with Mtb72F, delivered either as DNA or as a rAg-based vaccine, resulted in prolonged survival (>1 year) after aerosol challenge with virulent M. tuberculosis comparable to bacillus Calmette-Guérin immunization. Mtb72F in AS02A formulation is currently in phase I clinical trial, making it the first recombinant tuberculosis vaccine to be tested in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection.
Flynn, J. L., Chan, J., Triebold, K. J., Dalton, D. K., Stewart, T. A., & Bloom, B. R. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.6.2249 · Cited by 2,465
Disseminated tuberculosis in interferon gamma gene-disrupted mice.
Cooper, A. M., Dalton, D. K., Stewart, T. A., Griffin, J. P., Russell, D. G., & Orme, I. M. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.6.2243 · Cited by 1,986
Self-citationEfficacy of BCG Vaccine in the Prevention of Tuberculosis: Meta-analysis of the Published Literature
Colditz, G. A. (1994) · JAMA · doi:10.1001/jama.1994.03510330076038 · Cited by 1,918
A Mutation in the Interferon-γ –Receptor Gene and Susceptibility to Mycobacterial Infection
Newport, M. J., Huxley, C. M., Huston, S., Hawrylowicz, C. M., Oostra, B. A., Williamson, R., & Levin, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352602 · Cited by 1,199
Interferon-γ –Receptor Deficiency in an Infant with Fatal Bacille Calmette–Guérin Infection
Jouanguy, E., Altare, F., Lamhamedi, S., Revy, P., Emile, J.-F., Newport, M., Levin, M., Blanche, S., Seboun, E., Fischer, A., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352604 · Cited by 895
Flynn, J. L., Goldstein, M. M., Triebold, K. J., Koller, B., & Bloom, B. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.24.12013 · Cited by 792
Global tuberculosis incidence and mortality during 1990-2000.
Pj, D., Raviglione, M. C., & Kochi, A. (1994) · PubMed · Cited by 768
Kensil, C. R., Patel, U., Lennick, M., & Marciani, D. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.2.431 · Cited by 654
Adjuvants for human vaccines—current status, problems and future prospects
Gupta, R. K., & Siber, G. R. (1995) · Vaccine · doi:10.1016/0264-410x(95)00011-o · Cited by 551
Tuberculosis: a global overview of the situation today.
Sudre, P., ten Dam, G., & Kochi, A. (1992) · Europe PMC (PubMed Central) · Cited by 539
Cited by
The success and failure of BCG — implications for a novel tuberculosis vaccine
Andersen, P., & Doherty, T. M. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1211 · Cited by 788
A multistage tuberculosis vaccine that confers efficient protection before and after exposure
Aagaard, C., Hoang, T., Dietrich, J., Cardona, P.-J., Izzo, A., Dolganov, G., Schoolnik, G. K., Cassidy, J. P., Billeskov, R., & Andersen, P. (2011) · Nature Medicine · doi:10.1038/nm.2285 · Cited by 527
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives
Garçon, N., Chomez, P., & Van Mechelen, M. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.5.723 · Cited by 476
Use of defined TLR ligands as adjuvants within human vaccines
Duthie, M. S., Windish, H. P., Fox, C. B., & Reed, S. G. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00978.x · Cited by 437
Self-citationNewton, S. M., Brent, A. J., Anderson, S., Whittaker, E., & Kampmann, B. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70182-8 · Cited by 480
Phase 2b Controlled Trial of M72/AS01 E Vaccine to Prevent Tuberculosis
Van Der Meeren, O., Hatherill, M., Nduba, V., Wilkinson, R. J., Muyoyeta, M., Van Brakel, E., Ayles, H. M., Henostroza, G., Thienemann, F., Scriba, T. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1803484 · Cited by 413
The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus
Karlsson Hedestam, G. B., Fouchier, R. A. M., Phogat, S., Burton, D. R., Sodroski, J., & Wyatt, R. T. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1819 · Cited by 339
Unmet needs in modern vaccinology
Leroux-Roels, G. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.07.021 · Cited by 304
Advances in tuberculosis vaccine strategies
Skeiky, Y. A. W., & Sadoff, J. C. (2006) · Nature Reviews Microbiology · doi:10.1038/nrmicro1419 · Cited by 299
Self-citationAgger, E. M., Rosenkrands, I., Hansen, J., Brahimi, K., Vandahl, B. S., Aagaard, C., Werninghaus, K., Kirschning, C., Lang, R., Christensen, D., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003116 · Cited by 287
Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis
Kaufmann, S. H. E., & McMichael, A. J. (2005) · Nature Medicine · doi:10.1038/nm1221 · Cited by 273
Metadata
- Authors
- Skeiky, Y. A. W., Alderson, M. R., Ovendale, P. J., Guderian, J. A., Brandt, L., Dillon, D. C., Campos-Neto, A., Lobet, Y., Dalemans, W., Orme, I. M., & Reed, S. G.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-06
- Volume
- 172
- Issue
- 12
- Pages
- 7618-7628
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1582232949
- Cited by
- 313
- References
- 49
- FWCI
- 19.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.